Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations, By Therapeutic Area, By Gene Delivery Method, By Region, And Segment Forecasts, 2023 To 2030

The AAV virus vector manufacturing market is anticipated to witness significant growth owing to its simple structure, lack of disease correlation, and unique biology which has also gained huge interest in the healthcare community. Moreover, several AVV-based therapies have been developed for the treatment of diseases such as cystic fibrosis, Duchenne muscular dystrophy, and retinitis pigmentosa. For instance, in October 2022, Taysha GTx. and Astellas Pharma Inc announced to offer funding to support the advancement of Taysha's AAV gene therapy development program for the treatment of giant axonal neuropathy (GAN) and Rett syndrome. 

Furthermore, advancements in the efficiency of gene delivery to treat diseases through adeno-associated viruses along with the advances in manufacturing approaches have accelerated interest in drug development for gene therapies. In February 2021, an article published by Wyss Institute stated that adeno-associated virus has been considered as the primary vector for in vivo delivery of therapeutic genes as they are non-pathogenic and it can effectively target several tissue and cell types. FDA authorized several vector-based gene therapies for spinal muscular atrophy treatment and rare retinal dystrophy treatment that highlights the promise of the therapeutic modality. 

Moreover, according to FDA, approximately 10-20 gene therapy products will be authorized by 2025. The increase in the development of these therapies could be due to the introduction of effective and safe gene delivery vectors like an adeno-associated virus. The significant potential of the vector has been determined by the authorization of two AAV-based gene therapy products and its use in more than 100 clinical trials. Despite its potential application in certain clinical settings, the use of AAV-based gene therapy remains limited due to issues linked to host immunity. This may be one of the factor which could restrict the Adeno Associated Virus vector (AAV) manufacturing market growth. 

Several developments by the market players such as new product launches, mergers, and acquisitions have positively impacted the market growth. For instance, In August 2022, Merck KGaA announced of launching the VirusExpress 293 adeno-associated virus production platform, which makes the company CDMO and a technology developer to offer full viral vector manufacturing, including Lentiviral, CTO, CDMO, and process development. This would help biopharmaceutical companies to enhance the speed of clinical manufacturing while lowering process development costs and time. 

                            AAV Vector Manufacturing Market Segmentation

Major players operating in the AAV vector manufacturing market include Roche (Spark Therapeutics), Biomarin Pharmaceutical, Oxford BioMedica, WuXi AppTec, YPOSKESI, Sarepta Therapeutics, Pfizer, Audentes Therapeutics.